Hugh James Freeman, Department of Medicine (Gastroenterology), University of British Columbia, Vancouver V6T 1W5, Canada
Author contributions: Freeman HJ contributed all to this paper.
Correspondence to: Dr. Hugh James Freeman, MD, FRCPC, FACP, Department of Medicine Gastroenterology, University of British Columbia, 2211 Wesbrook Mall, Vancouver V6T 1W5, Canada. firstname.lastname@example.org
Telephone: +1-604-8227216 Fax: +1-604-8227236
Received: November 10, 2007 Revised: January 10, 2008
Fundic gland polyps are now commonly recognized during endoscopy. These polyps are benign, often multiple and usually detected in the gastric body and fundus. In the past, these polyps were sometimes associated with familial adenomatous polyposis. In recent years, it has become evident that increasing numbers of these polyps are being detected during endoscopic studies, particularly in patients treated with proton pump inhibitors for prolonged periods. In some, dysplastic changes in these polyps have also been reported. Recent studies have suggested that there may be no increase in risk of colon cancer with long-term proton pump inhibitor therapy. While temporarily reassuring, ongoing vigilance, particularly in those genetically predisposed to colon cancer, is still warranted.
© 2008 WJG. All rights reserved.
Key words: Gastric polyps; Fundic gland polyposis; Gastric dysplasia; Gastric cancer; Colon polyps; Familial polyposis coli; Adenomatous polyposis coli gene mutation
Peer reviewer: Volker F Eckardt, Chief, MD, Professor, Department of Gastroenterology, Deutsche Klinik für Diagnostik, Aukammallee 33, 65191 Wiesbaden, Germany
Freeman HJ. Proton pump inhibitors and an emerging epidemic of gastric fundic gland polyposis. World J Gastroenterol 2008; 14(9): 1318-1320 Available from: URL: http://www.wjgnet.com/1007-9327/14/1318.asp DOI: http://dx.doi.org/10.3748/wjg.14.1318
Gastric polyps and tumors have been classified into mucosal, lymphoid, mesenchymal and stromal types. Both neoplastic (adenoma, carcinoma, carcinoids) and non-neoplastic mucosal types occur. Most neoplastic epithelial polyps are asymptomatic and, usually, occur in the gastric antrum. Occasionally, these polyps bleed or present with an iron deficiency anemia. Rarely, gastric adenomas, particularly if large and pedunculated, cause symptoms from intermittent gastric outlet obstruction due to duodenal prolapse. Carcinoma may also complicate such adenomas. But, even these complex malignant polyps have been amenable to endoscopic resection.
FUNDIC GLAND POLYPOSIS
One of the most common types of gastric polyps, generally classified as non-neoplastic, is the sporadic fundic gland polyp. Usually, these are confined to the gastric body and fundus and rarely cause symptoms. Fundic gland polyps are typically detected during investigation for abdominal pain, dyspepsia or chronic reflux. Historically, it has been estimated that these polyps occur in up to 2% of all endoscopic studies. Although quite characteristic, they were only first described as a distinct pathological type in 1977. Previously, these were reported to occur most often in females and were thought to be derived from the parietal cell- and chief cell-bearing region of the gastric mucosa. Cystic dilation of pits deep in the mucous neck cells was observed with mucous cells, chief cells and parietal cells lining these mucosal cysts. Inflammatory changes in these polyps is usually minimal or absent. It has been reported that these polyps may resolve spontaneously.
FAMILIAL ADENOMATOUS POLYPOSIS (FAP)
Gastric polyps also occur in the majority of patients with FAP, screened with endoscopy[5-7]. FAP results from inherited germline mutations in the adenomatous polyposis coli (APC) gene, coupled with second somatic mutations. This leads to inactivation of both copies of the APC tumor suppressor gene[8,9]. Importantly, the most common gastric lesion in FAP is the syndromic fundic gland polyp, histologically similar to sporadic fundic gland polyps. Gastric and duodenal adenomas also occur in FAP, but are much less common. Fundic gland polyps are most often not associated with FAP and have little or no potential for malignant transformation[5,10]. However, high-grade dysplasia and gastric adenocarcinoma have both been associated with fundic gland polyps in FAP[7,11-15]. As a result, colonoscopic surveillance has been suggested to determine if FAP or an attenuated form of FAP is present when fundic gland polyps are first detected. Evidence strongly supporting this approach is not available. As fundic gland polyps are being increasingly recognized during endoscopic evaluations, added colonoscopic studies might be best reserved for those with concomitant gastric or duodenal adenomas.
MOLECULAR GENETIC MARKERS
Since both sporadic and syndromic FAP-associated fundic gland polyps have similar histological appearances, genetic markers have been explored to determine if there are additional similarities or differences. Distinct disruptions in the Wnt signaling pathway with activating beta-catenin mutations occur with sporadic polyps, while FAP-associated polyps showed second, somatic mutations of the APC gene. With chronic acid suppression therapy, multiple fundic gland polyps develop that are also histologically and genetically identical to single sporadic polyps. In these, beta-catenin mutations were detected in most polyps. In addition, distinct mutations in different polyps from the same individual indicated a multifocal origin for the polyps. Separate studies on fundic gland polyps in the absence of FAP have also failed to show APC gene deletions. Interestingly, a very low prevalence of H pylori infection was also noted with these polyps. In contrast, APC gene mutations were found in FAP with both syndromic fundic gland polyps and high grade dysplasia in gastric epithelium. While these studies have served to elucidate molecular changes in sporadic and syndromic (FAP) gastric fundic gland polyps, more information is needed to determine if these markers could be used cost-effectively to predict risk in fundic gland polyps for eventual development of gastric cancer.
PROTON PUMP INHIBITOR-ASSOCIATED GASTRIC POLYPS
Omeprazole was first introduced for clinical use as a proton pump inhibitor in 1988. Since then, worldwide sales figures for proton pump inhibitors have dramatically risen with estimated sales now totaling over $10 billion and rising. Over 720 million prescriptions for proton pump inhibitors have been written worldwide, largely for long-term use, while large randomized clinical trials have confirmed the high efficacy and safety profile of long-term treatment. In addition, however, substantial physiological changes occur with chronic acid suppression therapy. Increased levels of circulating gastrin occur. This hormone stimulates increased cell proliferation. Chronic ECL cell stimulation also results as reflected by increased levels of chromogranin A, an endocrine cell product. In recent years, gastric fundic gland polyps have become increasingly detected in patients on long-term proton pump inhibitor therapy[23-26]. These fundic gland polyps are often multiple in this setting and localized in the gastric body and fundus. No definite sex predilection has been defined. They appear to have similar histologic and genetic features to those developing without proton pump inhibitor use. Recent studies have defined a relationship between the length of drug use, especially after 12 mo, and increased polyp risk. In addition, most patients with fundic gland polyps on proton pump inhibitors are H pylori-negative, consistent with a previous report of fundic gland polyp regression following acquisition of H pylori. Of concern, multiple fundic gland polyps have also been noted in some children on long-term omeprazole therapy[28,29]. Moreover, in a pediatric FAP population on proton pump inhibitors for more than 6 mo, dysplasia was reported in fundic gland polyps. These studies imply that with increasing use of long-term proton pump inhibitors, an epidemic of fundic gland polyposis will be defined. Studies are needed to determine if further follow-up of patients on long-term therapy with proton pump inhibitors and fundic gland polyps is warranted. In spite of an early record of safety with long-term use, there remain concerns regarding the potential risk of cancer with long-term exposure, not only in those with FAP, but also in those genetically predisposed to cancer. This concern is reflected in the recently published studies on colon cancer risk with long-term proton pump inhibitor exposure. In these studies, no increased risk was shown[30,31]. While temporarily re-assuring, ongoing vigilance will be required before the final chapter is written.
1 Lewin KJ, Riddell RH, Weinstein WM. Gastrointestinal Pathology and Its Clinical Implications. New York, Tokyo: Igaku- Shoin, 1992: 610
2 Freeman HJ. Endoscopic excision of a prolapsing malignant polyp which caused intermittent gastric outlet obstruction. World J Gastroenterol 2005; 11: 5245-5247 PubMed
3 Elster K, Eidt H, Ottenjann R, Rosch W, Seifert E. Drusenkor-perzysten, eine polypoide Lasion der Magenschleimhaut. Deutsch Med Wochenschr 1977; 102: 183-187
4 Iida M, Yao T, Watanabe H, Imamura K, Fuyuno S, Omae T. Spontaneous disappearance of fundic gland polyposis: report of three cases. Gastroenterology 1980; 79: 725-728 PubMed
5 Sarre RG, Frost AG, Jagelman DG, Petras RE, Sivak MV, McGannon E. Gastric and duodenal polyps in familial adenomatous polyposis: a prospective study of the nature and prevalence of upper gastrointestinal polyps. Gut 1987; 28: 306-314 PubMed
6 Watanabe H, Enjoji M, Yao T, Ohsato K. Gastric lesions in familial adenomatosis coli: their incidence and histologic analysis. Hum Pathol 1978; 9: 269-283 PubMed
7 Domizio P, Talbot IC, Spigelman AD, Williams CB, Phillips RK. Upper gastrointestinal pathology in familial adenomatous polyposis: results from a prospective study of 102 patients. J Clin Pathol 1990; 43: 738-743 PubMed
8 Toyooka M, Konishi M, Kikuchi-Yanoshita R, Iwama T, Miyaki M. Somatic mutations of the adenomatous polyposis coli gene in gastroduodenal tumors from patients with familial adenomatous polyposis. Cancer Res 1995; 55: 3165-3170
9 Abraham SC, Nobukawa B, Giardiello FM, Hamilton SR, Wu TT. Fundic gland polyps in familial adenomatous polyposis: neoplasms with frequent somatic adenomatous polyposis coli gene alterations. Am J Pathol 2000; 157: 747-754 PubMed
10 Odze RD, Marcial MA, Antonioli D. Gastric fundic gland polyps: a morphological study including mucin histochemistry, stereometry, and MIB-1 immunohistochemistry. Hum Pathol 1996; 27: 896-903 PubMed
11 Coffey RJ Jr, Knight CD Jr, van Heerden JA, Weiland LH. Gastric adenocarcinoma complicating Gardner's syndrome in a North American woman. Gastroenterology 1985; 88: 1263-1266 PubMed
12 Goodman AJ, Dundas SA, Scholefield JH, Johnson BF. Gastric carcinoma and familial adenomatous polyposis (FAP). Int J Colorectal Dis 1988; 3: 201-203 PubMed
13 Odze RD, Quinn PS, Terrault NA, Vivona AA, Ward MA, Cohen Z, Gallinger S. Advanced gastroduodenal polyposis with ras mutations in a patient with familial adenomatous polyposis. Hum Pathol 1993; 24: 442-448 PubMed
14 Zwick A, Munir M, Ryan CK, Gian J, Burt RW, Leppert M, Spirio L, Chey WY. Gastric adenocarcinoma and dysplasia in fundic gland polyps of a patient with attenuated adenomatous polyposis coli. Gastroenterology 1997; 113: 659-663 PubMed
15 Hofgartner WT, Thorp M, Ramus MW, Delorefice G, Chey WY, Ryan CK, Takahashi GW, Lobitz JR. Gastric adenocarcinoma associated with fundic gland polyps in a patient with attenuated familial adenomatous polyposis. Am J Gastroenterol 1999; 94: 2275-2281 PubMed
16 Declich P, Tavani E, Ferrara A, Caruso S, Bellone S. Sporadic fundic gland polyps: clinico-pathologic features and associated diseases. Pol J Pathol 2005; 56: 131-137 PubMed
17 Declich P, Isimbaldi G, Sironi M, Galli C, Ferrara A, Caruso S, Baldacci MP, Stioui S, Privitera O, Boccazzi G, Federici S. Sporadic fundic gland polyps: an immunohistochemical study of their antigenic profile. Pathol Res Pract 1996; 192: 808-815 PubMed
18 Torbenson M, Lee JH, Cruz-Correa M, Ravich W, Rastgar K, Abraham SC, Wu TT. Sporadic fundic gland polyposis: a clinical, histological, and molecular analysis. Mod Pathol 2002; 15: 718-723 PubMed
19 Shand AG, Taylor AC, Banerjee M, Lessels A, Coia J, Clark C, Haites N, Ghosh S. Gastric fundic gland polyps in south- east Scotland: absence of adenomatous polyposis coli gene mutations and a strikingly low prevalence of Helicobacter pylori infection. J Gastroenterol Hepatol 2002; 17: 1161-1164 PubMed
20 Sekine S, Shimoda T, Nimura S, Nakanishi Y, Akasu T, Katai H, Gotoda T, Shibata T, Sakamoto M, Hirohashi S. High- grade dysplasia associated with fundic gland polyposis in a familial adenomatous polyposis patient, with special reference to APC mutation profiles. Mod Pathol 2004; 17: 1421-1426 PubMed
21 Raghunath AS, O'Morain C, McLoughlin RC. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther 2005; 22 Suppl 1: 55-63 PubMed
22 Fossmark R, Jianu CS, Martinsen TC, Qvigstad G, Syversen U, Waldum HL. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition. Scand J Gastroenterol 2007; 1-5 PubMed
23 Graham JR. Gastric polyposis: onset during long-term therapy with omeprazole. Med J Aust 1992; 157: 287-288 PubMed
24 el-Zimaity HM, Jackson FW, Graham DY. Fundic gland polyps developing during omeprazole therapy. Am J Gastroenterol 1997; 92: 1858-1860 PubMed
25 Choudhry U, Boyce HW Jr, Coppola D. Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics. Am J Clin Pathol 1998; 110: 615-621 PubMed
26 Jalving M, Koornstra JJ, Wesseling J, Boezen HM, DE Jong S, Kleibeuker JH. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 2006; 24: 1341-1348 PubMed
27 Watanabe N, Seno H, Nakajima T, Yazumi S, Miyamoto S, Matsumoto S, Itoh T, Kawanami C, Okazaki K, Chiba T. Regression of fundic gland polyps following acquisition of Helicobacter pylori. Gut 2002; 51: 742-745 PubMed
28 Pashankar DS, Israel DM. Gastric polyps and nodules in children receiving long-term omeprazole therapy. J Pediatr Gastroenterol Nutr 2002; 35: 658-662 PubMed
29 Attard TM, Yardley JH, Cuffari C. Gastric polyps in pediatrics: an 18-year hospital-based analysis. Am J Gastroenterol 2002; 97: 298-301 PubMed
30 Robertson DJ, Larsson H, Friis S, Pedersen L, Baron JA, Sorensen HT. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology 2007; 133: 755-760 PubMed
31 Yang YX, Hennessy S, Propert K, Hwang WT, Sedarat A, Lewis JD. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology 2007; 133: 748-754 PubMed
S- Editor Li DL L -Editor Alpini GD E- Editor Wang HF